Sutro Biopharma, Inc.

STRO

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001382101

E

weakest fifth of 370 graded peers in healthcare

rank 344 of 370; percentile 93.0; sampling error 2.5 points; lower is stronger

A B C D E

E, the bear




Scoreboard	
Profitability	C/D percentile 61.4
Solvency	D/E percentile 79.1
Growth and financing	D percentile 70.1
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $173.8M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	dilution, short runway, distress; fortre...
Inputs computable	7 of 14
Graded from	filings received through Mar 23, 2026 211 days before the rescan; latest periodic filing 10-Q received Aug 12, 2026
Last close	$11.25 2026-10-19; market equity $186.5M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 23, 2026

We are a clinical stage oncology company developing site-specific and novel-format antibody drug conjugates, or ADCs, enabled by our proprietary integrated cell-free protein synthesis platform, XpressCF®, and our site-specific conjugation platform, XpressCF+®. We aim to design and develop therapeutics using the most relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, or iADCs, and dual-payload ADCs, or dpADCs. Our molecules are directed primarily against clinically validated targets where the current standard of care is suboptimal.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 61.4						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

pretax income must exceed the validity floor and imply a 0%-100% tax rate						
Accruals ratio	(4.9%)	(6.6%)		61.4	812	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 79.1						
Twelve-month failure probability	1.44%	0.06%		90.7	247	2026-06-30
Altman Z double-prime	(22.06)	(0.30)		75.1	757	2025-12-31
Net debt to EBITDA	not computable	1.82x				
EBITDA must exceed $100,000						
Interest coverage	not computable	(4.51x)				
latest aligned inputs end 2018-12-31; latest annual assets end 2025-12-31						
Current ratio	2.01x	2.96x		71.4	840	2025-12-31
Growth and financing, sleeve percentile 70.1						
Revenue growth, three-year compound	14.8%	10.1%		39.5	414	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%				
four consecutive annual FCF observations are required; found 1						
Reinvestment rate	not computable	37.1%				
required facts have no common fiscal period end						
Asset growth, three years	(24.7%)	2.1%		88.4	705	2025-12-31
Net share issuance, one year	97.8%	2.5%		82.6	634	2026-03-16


Warnings

4 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 97.8%
Short runway	cash runway is 4.5 months
Distress	CHS probability 1.438164%; universe top-decile threshold 0.908785%
Fortress balance sheet	cash minus debt is 65,207,000 USD; Altman Z is not used

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
339	Century Therapeutics, Inc. (IPSC)	91.6	E	dilution, fortress balance sheet
340	Beyond Air, Inc. (XAIR)	91.9	E	dilution, short runway, distress
341	Precision Biosciences Inc. (DTIL)	92.1	E	dilution, fortress balance sheet
342	Airsculpt Technologies, Inc. (AIRS)	92.4	E	late filer
343	Elutia Inc. (ELUT)	92.7	E	short runway, fortress balance sheet
344	Sutro Biopharma, Inc. (STRO)	93.0	E	dilution, short runway, distress, fortress balance sheet
345	China Pharma Holdings, Inc. (CPHI)	93.2	E	dilution, late filer
346	Fortress Biotech, Inc. (FBIO)	93.6	E	fortress balance sheet
347	Fortress Biotech, Inc. (FBIOP)	93.6	E	fortress balance sheet

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

348	Co-Diagnostics, Inc. (CODX)	94.0	E	dilution, short runway, fortress balance sheet
349	Celularity Inc. (CELU)	94.3	E	short runway, late filer

What the price implies

at the 2026-10-19 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	133.1%	8.0%	92
Distance from 52-week high	(72.5%)	(31.9%)	11
EBIT to enterprise value	(116.1%)	(1.6%)	5
Free cash flow yield	6.0%	(1.0%)	86
Book value to price	(0.55)	0.28	4
Sales to price	0.55	0.31	69
Composite equity issuance, five years	128.5%	20.3%	83
Relative strength against the sector, log excess return	0.63	(0.13)	92

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$54.3M
Operating cash flow, four quarters	-$145.2M
Months of runway	4.5
Days since last periodic filing	69 (10-Q received Aug 12, 2026)
Median daily dollar volume, 63 sessions	$4.0M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	operating income	us-gaap:OperatingIncomeLoss	-$89.3M	2023-12-31	2025-03-13	10-K	25-038884
2	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$88.6M	2023-12-31	2025-03-13	10-K	25-038884
3	income tax	us-gaap:IncomeTaxExpenseBenefit	$18.2M	2023-12-31	2025-03-13	10-K	25-038884
4	total debt	us-gaap:LongTermDebt	$4.1M	2023-12-31	2024-03-25	10-K	24-035949
5	book equity	us-gaap:StockholdersEquity	$149.6M	2023-12-31	2026-03-23	10-K	26-119873
6	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$69.3M	2023-12-31	2025-03-13	10-K	25-038884
7	total debt	us-gaap:LongTermDebt	$16.3M	2022-12-31	2024-03-25	10-K	24-035949
8	book equity	us-gaap:StockholdersEquity	$217.0M	2022-12-31	2025-03-13	10-K	25-038884
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$47.3M	2022-12-31	2025-03-13	10-K	25-038884
10	net income	us-gaap:NetIncomeLoss	-$191.1M	2025-12-31	2026-03-23	10-K	26-119873
11	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$177.2M	2025-12-31	2026-03-23	10-K	26-119873
12	assets	us-gaap:Assets	$173.8M	2025-12-31	2026-03-23	10-K	26-119873
13	assets	us-gaap:Assets	$387.2M	2024-12-31	2026-03-23	10-K	26-119873
14	current assets	us-gaap:AssetsCurrent	$150.9M	2025-12-31	2026-03-23	10-K	26-119873

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

15	current liabilities	us-gaap:LiabilitiesCurrent	$75.1M	2025-12-31	2026-03-23	10-K	26-119873
16	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$978.0M	2025-12-31	2026-03-23	10-K	26-119873
17	operating income	us-gaap:OperatingIncomeLoss	-$158.4M	2025-12-31	2026-03-23	10-K	26-119873
18	book equity	us-gaap:StockholdersEquity	-$132.5M	2025-12-31	2026-03-23	10-K	26-119873
19	liabilities	us-gaap:Liabilities	$306.3M	2025-12-31	2026-03-23	10-K	26-119873
20	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$6.8M	2023-12-31	2025-03-13	10-K	25-038884
21	operating income	us-gaap:OperatingIncomeLoss	-$37.2M	2018-12-31	2021-03-18	10-K	21-013945
22	interest expense	us-gaap:InterestExpense	$1.6M	2018-12-31	2019-04-01	10-K	19-010253
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$102.5M	2025-12-31	2026-03-23	10-K	26-119873
24	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$62.0M	2024-12-31	2026-03-23	10-K	26-119873
25	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$153.7M	2023-12-31	2025-03-13	10-K	25-038884
26	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$67.8M	2022-12-31	2025-03-13	10-K	25-038884
27	assets	us-gaap:Assets	$470.7M	2023-12-31	2025-03-13	10-K	25-038884
28	assets	us-gaap:Assets	$406.9M	2022-12-31	2024-03-25	10-K	24-035949
29	shares outstanding	dei:EntityCommonStockSharesOutstanding	16,567,238	2026-03-16	2026-03-23	10-K	26-119873
30	shares outstanding	dei:EntityCommonStockSharesOutstanding	83,775,336	2025-03-06	2025-03-13	10-K	25-038884

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.